Bleeding Work-Up for Newborn with Intraventricular Hemorrhage
For a newborn with intraventricular hemorrhage, obtain a complete blood count with platelet count, prothrombin time (PT/INR), activated partial thromboplastin time (aPTT), and fibrinogen level to identify coagulopathy or thrombocytopenia as potential contributors to bleeding.
Initial Laboratory Assessment
The bleeding work-up should focus on identifying acquired or inherited coagulation abnormalities that may have contributed to or resulted from the IVH:
Essential First-Line Tests
Complete blood count (CBC) with platelet count: Thrombocytopenia (platelets <100 × 10⁹/L) is associated with increased risk of IVH in neonates 1. While isolated thrombocytopenia rarely presents as a hemorrhagic emergency, it becomes clinically significant when coupled with coagulation factor deficiencies 2.
Coagulation studies:
- PT/INR and aPTT to assess clotting factor function
- Fibrinogen level (normal >1.5 g/L; concerning if <1.0 g/L)
Approximately 50% of term neonates with IVH have demonstrable coagulopathy 3, making these studies essential rather than optional.
Context-Specific Considerations
Maternal and Birth History
Critical historical elements that guide further work-up:
Maternal medications during pregnancy: Warfarin, phenytoin, or barbiturates can cause vitamin K-dependent coagulation factor deficiency in the newborn 4. These infants require higher doses of vitamin K after birth.
Vitamin K prophylaxis status: Confirm whether vitamin K was administered at birth. Vitamin K deficiency bleeding can cause catastrophic intracranial hemorrhage 5.
Gestational age: The pathophysiology differs between preterm and term infants. In preterm infants, IVH typically originates from germinal matrix rupture due to immature, fragile vasculature 6. In term neonates, the choroid plexus is the most common source (60%), followed by germinal matrix (20%) 3.
Additional Testing Based on Initial Results
If coagulopathy is identified (prolonged PT/aPTT, low fibrinogen):
- Consider protein C and protein S levels if severe coagulopathy suggests homozygous protein C deficiency [@2-8,@10@]
- Assess for disseminated intravascular coagulation (DIC) if multiple abnormalities present
If thrombocytopenia is present:
- Investigate etiology: isoimmune thrombocytopenia, maternal ITP, sepsis, or congenital disorders
- In term neonates, thrombocytopenia-absent radius syndrome should be considered if severe thrombocytopenia exists [@1@]
Common Pitfalls to Avoid
Don't assume IVH is purely mechanical in preterm infants: While germinal matrix fragility is the primary issue in prematurity, up to 50% of cases have identifiable coagulation abnormalities that require treatment [@15@].
Don't overlook maternal drug exposure: Specifically ask about anticonvulsants and anticoagulants during pregnancy, as these directly impact neonatal coagulation [@1@].
Don't delay vitamin K administration: If not given at birth and coagulopathy is present, administer vitamin K immediately while awaiting laboratory results.
Don't forget to assess for underlying vascular malformations in term infants: While less common in neonates than older children, arteriovenous malformations and other vascular anomalies can present with IVH [@1@]. Consider neuroimaging beyond ultrasound if the clinical picture is atypical.
Risk Stratification
The work-up intensity should match the clinical severity:
- Grade I-II IVH with stable infant: Basic coagulation panel and platelet count suffice
- Grade III-IV IVH or clinical deterioration: Comprehensive evaluation including fibrinogen, consideration of factor assays, and close monitoring for progression
- Recurrent or unexplained bleeding: Expand work-up to include thrombophilia screening and consideration of inherited bleeding disorders
The evidence shows that while most neonates with IVH (83.3%) are discharged in good condition [@15